1. 1. Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E (2003) A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol, 42(5-6): 620-33. [DOI:10.1080/02841860310014895] [PMID]

2. Lutz S, Berk L, Chang E, et al. (2011) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys, 79(4): 965-76. [DOI:10.1016/j.ijrobp.2010.11.026] [PMID]

3. Na F, Wang J, Li C, et al. (2014) Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol, 9(6): 834-42. [DOI:10.1097/JTO.0000000000000185] [PMID] []

4. Higgins KA, Hoang JK, Roach MC, et al. (2012) Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys, 82(2): 548-53. [DOI:10.1016/j.ijrobp.2010.11.050] [PMID]

5. Rodríguez-Fraile M, Cózar-Santiago MP, Sabaté-Llobera A, et al. (2020) FDG PET/CT in colorectal cancer. Rev Esp Med Nucl Imagen Mol (Engl Ed), 39(1): 57-66. [DOI:10.1016/j.remnie.2019.12.001]

6. Kim N, Cho H, Yun M, et al. (2019) Prognostic values of mid-radiotherapy 18F-FDG PET/CT in patients with esophageal cancer. Radiat Oncol, 14(1): 27. [DOI:10.1186/s13014-019-1232-1] [PMID] []

7. Han S, Kim H, Kim YJ, et al. (2018) Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in uterine cervical cancer: A systematic review and meta-analysis. AJR Am J Roentgenol, 211(5): 1112-1121. [DOI:10.2214/AJR.18.19734] [PMID]

8. Zhao F, Ding G, Huang W, et al. (2015) FDG-PET predicts pain response and local control in palliative radiotherapy with or without systemic treatment in patients with bone metastasis from non-small-cell lung cancer. Clin Lung Cancer, 16(6): e111-9. [DOI:10.1016/j.cllc.2015.01.005] [PMID]

9. Choi SH, Chang JS, Jeong YH, et al. (2014) FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma. Liver Int, 34(7): 1118-25. [DOI:10.1111/liv.12487] [PMID]

10. Tateishi U, Gamez C, Dawood S, et al. (2008) Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology, 247(1): 189-96. [DOI:10.1148/radiol.2471070567] [PMID]

11. Tahara T, Fujii S, Ogawa T, et al. (2016) Fluorodeoxyglucose uptake on positron emission tomography is a useful predictor of long-term pain control after palliative radiation therapy in patients with painful bone metastases: Results of a single-institute prospective study. Int J Radiat Oncol Biol Phys, 94(2): 322-8. [DOI:10.1016/j.ijrobp.2015.10.036] [PMID]

12. Adli M, Kuzhan A, Alkis H, et al. (2013) FDG PET uptake as a predictor of pain response in palliative radiation therapy in patients with bone metastasis. Radiology, 269(3): 850-6. [DOI:10.1148/radiol.13121981] [PMID]

13. Delbeke D, Coleman RE, Guiberteau MJ, et al. (2006) Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med, 47(5): 885-95.

14. Chow E, Hoskin P, Mitera G, et al. (2012) Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Int J Radiat Oncol Biol Phys, 82(5):1730-7. [DOI:10.1016/j.ijrobp.2011.02.008] [PMID]

15. Li C, Lan X, Yuan H, et al. (2014) 18F-FDG PET predicts pathological response to preoperative chemoradiotherapy in patients with primary rectal cancer: a meta-analysis. Ann Nucl Med, 28(5): 436-46. [DOI:10.1007/s12149-014-0837-6] [PMID]

16. Yoshioka M, Sato T, Furuya T, et al. (2004) Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer. J Gastroenterol, 39(1): 50-5. [DOI:10.1007/s00535-003-1244-2] [PMID]

17. Borst GR, Belderbos JS, Boellaard R, et al. (2005) Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer, 41(11): 1533-41. [DOI:10.1016/j.ejca.2005.03.026] [PMID]

18. Yao M, Smith RB, Graham MM, et al. (2005) The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys, 63(4): 991-9. [DOI:10.1016/j.ijrobp.2005.03.066] [PMID]

19. Allal AS, Slosman DO, Kebdani T, et al. (2004) Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys, 59(5):1295-300. [DOI:10.1016/j.ijrobp.2003.12.039] [PMID]

20. Calais J, Thureau S, Dubray B, et al. (2015) Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer. J Nucl Med, 56(2):196-203. [DOI:10.2967/jnumed.114.144253] [PMID]

21. Xiao W, Xu A, Han F, et al. (2015) Positron emission tomography-computed tomography before treatment is highly prognostic of distant metastasis in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy treatment: a prospective study with long-term follow-up. Oral Oncol, 51(4): 363-9. [DOI:10.1016/j.oraloncology.2015.01.009] [PMID]

22. Mizumoto M, Harada H, Asakura H, et al. (2008) Prognostic factors and a scoring system for survival after radiotherapy for metastases to the spinal column: a review of 544 patients at Shizuoka Cancer Center Hospital. Cancer, 113(10): 2816-22. [DOI:10.1002/cncr.23888] [PMID]

23. Choi Y, Kim J, Lee I, Seong J (2014) Dose escalation using helical tomotherapy improves local control in spine metastases from primary hepatic malignancies. Liver Int, 34(3): 462-8. [DOI:10.1111/liv.12260] [PMID]

24. Yamada Y, Bilsky MH, Lovelock DM, et al. (2008) High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys, 71(2): 484-90. [DOI:10.1016/j.ijrobp.2007.11.046] [PMID]